CGEN240517C5000
- 0.05
- 0.000.00%
Compugen Newsroom
Compugen Is Maintained at Buy by Truist Securities
Compugen Is Maintained at Buy by Truist Securities
Express News | Truist Securities Maintains Buy on Compugen, Lowers Price Target to $4
Compugen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/21/2024 118.58% Truist Securities $5 → $4 Maintains Buy 03/08/2024 173.22% Truist Securities $4 → $5 Ma
Express News | Compugen Ltd : Truist Securities Cuts Target Price to $4 From $5
Earnings Call Summary | Compugen(CGEN.US) Q1 2024 Earnings Conference
The following is a summary of the Compugen Ltd. (CGEN) Q1 2024 Earnings Call Transcript:Financial Performance:Compugen reported a cash balance of approximately $101.3 million as of Q1 2024, including
Truist Securities Trims Price Target on Compugen to $4 From $5, Maintains Buy Rating
Truist Securities Trims Price Target on Compugen to $4 From $5, Maintains Buy Rating.
PTC Therapeutics, Oragenics, GT Biopharma Among Healthcare Movers
Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates
Compugen (CGEN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.10.
Compugen Announces Promising Q1 2024 Updates
Express News | Compugen Expects Its Cash And Cash-related Balances Of $101.3M Together With A $30M Milestone Payment On COM503 IND Clearance Expected In 2024, Is Expected To Provide Cash Runway Into 2027
Compugen | 6-K: Report of foreign private issuer (related to financial reporting)
Compugen Q1 2024 GAAP EPS $(0.08) Beats $(0.11) Estimate, Sales $2.559M Miss $6.213M Estimate
Compugen Q1 2024 GAAP EPS $(0.08) Beats $(0.11) Estimate, Sales $2.559M Miss $6.213M Estimate
Earnings Flash (CGEN) COMPUGEN Reports Q1 Revenue $2.6M, Vs. Street Est of $1.2M
07:03 AM EDT, 05/20/2024 (MT Newswires) -- Earnings Flash (CGEN) COMPUGEN Reports Q1 Revenue $2.6M, vs. Street Est of $1.2M
Compugen 1Q Rev $2.56M >CGEN.TV
Compugen 1Q Rev $2.56M >CGEN.TV
Express News | Compugen Ltd: Solid Balance Sheet With Extended Cash Runway Expected to Fund Operations Into 2027
Compugen: Silberman Succeeds Alberto Sessa as Chief Financial Officer >CGEN
Compugen: Silberman Succeeds Alberto Sessa as Chief Financial Officer >CGEN
Express News | Compugen Ltd - Appointment of David Silberman as Its New Chief Financial Officer Effective August 15, 2024
Merck Discontinues Testing of Experimental Skin Cancer Combo Therapy
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Investors Don't See Light At End Of Compugen Ltd.'s (NASDAQ:CGEN) Tunnel And Push Stock Down 26%
Compugen Ltd. (NASDAQ:CGEN) shareholders that were waiting for something to happen have been dealt a blow with a 26% share price drop in the last month.